Feeds:
Posts
Comments

Archive for the ‘IP Development by LPBI Group Team’ Category

Will Web 3.0 Do Away With Science 2.0? Is Science Falling Behind?

Curator: Stephen J. Williams, Ph.D.

UPDATED 4/06/2022

A while back (actually many moons ago) I had put on two posts on this site:

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson and others

Twitter is Becoming a Powerful Tool in Science and Medicine

Each of these posts were on the importance of scientific curation of findings within the realm of social media and the Web 2.0; a sub-environment known throughout the scientific communities as Science 2.0, in which expert networks collaborated together to produce massive new corpus of knowledge by sharing their views, insights on peer reviewed scientific findings. And through this new media, this process of curation would, in itself generate new ideas and new directions for research and discovery.

The platform sort of looked like the image below:

 

This system lied above a platform of the original Science 1.0, made up of all the scientific journals, books, and traditional literature:

In the old Science 1.0 format, scientific dissemination was in the format of hard print journals, and library subscriptions were mandatory (and eventually expensive). Open Access has tried to ameliorate the expense problem.

Previous image source: PeerJ.com

To index the massive and voluminous research and papers beyond the old Dewey Decimal system, a process of curation was mandatory. The dissemination of this was a natural for the new social media however the cost had to be spread out among numerous players. Journals, faced with the high costs of subscriptions and their only way to access this new media as an outlet was to become Open Access, a movement first sparked by journals like PLOS and PeerJ but then begrudingly adopted throughout the landscape. But with any movement or new adoption one gets the Good the Bad and the Ugly (as described in my cited, above, Clive Thompson article). The bad side of Open Access Journals were

  1. costs are still assumed by the individual researcher not by the journals
  2. the arise of the numerous Predatory Journals

 

Even PeerJ, in their column celebrating an anniversary of a year’s worth of Open Access success stories, lamented the key issues still facing Open Access in practice

  • which included the cost and the rise of predatory journals.

In essence, Open Access and Science 2.0 sprung full force BEFORE anyone thought of a way to defray the costs

 

Can Web 3.0 Finally Offer a Way to Right the Issues Facing High Costs of Scientific Publishing?

What is Web 3.0?

From Wikipedia: https://en.wikipedia.org/wiki/Web3

Web 1.0 and Web 2.0 refer to eras in the history of the Internet as it evolved through various technologies and formats. Web 1.0 refers roughly to the period from 1991 to 2004, where most websites were static webpages, and the vast majority of users were consumers, not producers, of content.[6][7] Web 2.0 is based around the idea of “the web as platform”,[8] and centers on user-created content uploaded to social-networking services, blogs, and wikis, among other services.[9] Web 2.0 is generally considered to have begun around 2004, and continues to the current day.[8][10][4]

Terminology[edit]

The term “Web3”, specifically “Web 3.0”, was coined by Ethereum co-founder Gavin Wood in 2014.[1] In 2020 and 2021, the idea of Web3 gained popularity[citation needed]. Particular interest spiked towards the end of 2021, largely due to interest from cryptocurrency enthusiasts and investments from high-profile technologists and companies.[4][5] Executives from venture capital firm Andreessen Horowitz travelled to Washington, D.C. in October 2021 to lobby for the idea as a potential solution to questions about Internet regulation with which policymakers have been grappling.[11]

Web3 is distinct from Tim Berners-Lee‘s 1999 concept for a semantic web, which has also been called “Web 3.0”.[12] Some writers referring to the decentralized concept usually known as “Web3” have used the terminology “Web 3.0”, leading to some confusion between the two concepts.[2][3] Furthermore, some visions of Web3 also incorporate ideas relating to the semantic web.[13][14]

Concept[edit]

Web3 revolves around the idea of decentralization, which proponents often contrast with Web 2.0, wherein large amounts of the web’s data and content are centralized in the fairly small group of companies often referred to as Big Tech.[4]

Specific visions for Web3 differ, but all are heavily based in blockchain technologies, such as various cryptocurrencies and non-fungible tokens (NFTs).[4] Bloomberg described Web3 as an idea that “would build financial assets, in the form of tokens, into the inner workings of almost anything you do online”.[15] Some visions are based around the concepts of decentralized autonomous organizations (DAOs).[16] Decentralized finance (DeFi) is another key concept; in it, users exchange currency without bank or government involvement.[4] Self-sovereign identity allows users to identify themselves without relying on an authentication system such as OAuth, in which a trusted party has to be reached in order to assess identity.[17]

Reception[edit]

Technologists and journalists have described Web3 as a possible solution to concerns about the over-centralization of the web in a few “Big Tech” companies.[4][11] Some have expressed the notion that Web3 could improve data securityscalability, and privacy beyond what is currently possible with Web 2.0 platforms.[14] Bloomberg states that sceptics say the idea “is a long way from proving its use beyond niche applications, many of them tools aimed at crypto traders”.[15] The New York Times reported that several investors are betting $27 billion that Web3 “is the future of the internet”.[18][19]

Some companies, including Reddit and Discord, have explored incorporating Web3 technologies into their platforms in late 2021.[4][20] After heavy user backlash, Discord later announced they had no plans to integrate such technologies.[21] The company’s CEO, Jason Citron, tweeted a screenshot suggesting it might be exploring integrating Web3 into their platform. This led some to cancel their paid subscriptions over their distaste for NFTs, and others expressed concerns that such a change might increase the amount of scams and spam they had already experienced on crypto-related Discord servers.[20] Two days later, Citron tweeted that the company had no plans to integrate Web3 technologies into their platform, and said that it was an internal-only concept that had been developed in a company-wide hackathon.[21]

Some legal scholars quoted by The Conversation have expressed concerns over the difficulty of regulating a decentralized web, which they reported might make it more difficult to prevent cybercrimeonline harassmenthate speech, and the dissemination of child abuse images.[13] But, the news website also states that, “[decentralized web] represents the cyber-libertarian views and hopes of the past that the internet can empower ordinary people by breaking down existing power structures.” Some other critics of Web3 see the concept as a part of a cryptocurrency bubble, or as an extension of blockchain-based trends that they see as overhyped or harmful, particularly NFTs.[20] Some critics have raised concerns about the environmental impact of cryptocurrencies and NFTs. Others have expressed beliefs that Web3 and the associated technologies are a pyramid scheme.[5]

Kevin Werbach, author of The Blockchain and the New Architecture of Trust,[22] said that “many so-called ‘web3’ solutions are not as decentralized as they seem, while others have yet to show they are scalable, secure and accessible enough for the mass market”, adding that this “may change, but it’s not a given that all these limitations will be overcome”.[23]

David Gerard, author of Attack of the 50 Foot Blockchain,[24] told The Register that “web3 is a marketing buzzword with no technical meaning. It’s a melange of cryptocurrencies, smart contracts with nigh-magical abilities, and NFTs just because they think they can sell some monkeys to morons”.[25]

Below is an article from MarketWatch.com Distributed Ledger series about the different forms and cryptocurrencies involved

From Marketwatch: https://www.marketwatch.com/story/bitcoin-is-so-2021-heres-why-some-institutions-are-set-to-bypass-the-no-1-crypto-and-invest-in-ethereum-other-blockchains-next-year-11639690654?mod=home-page

by Frances Yue, Editor of Distributed Ledger, Marketwatch.com

Clayton Gardner, co-CEO of crypto investment management firm Titan, told Distributed Ledger that as crypto embraces broader adoption, he expects more institutions to bypass bitcoin and invest in other blockchains, such as Ethereum, Avalanche, and Terra in 2022. which all boast smart-contract features.

Bitcoin traditionally did not support complex smart contracts, which are computer programs stored on blockchains, though a major upgrade in November might have unlocked more potential.

“Bitcoin was originally seen as a macro speculative asset by many funds and for many it still is,” Gardner said. “If anything solidifies its use case, it’s a store of value. It’s not really used as originally intended, perhaps from a medium of exchange perspective.”

For institutions that are looking for blockchains that can “produce utility and some intrinsic value over time,” they might consider some other smart contract blockchains that have been driving the growth of decentralized finance and web 3.0, the third generation of the Internet, according to Gardner. 

Bitcoin is still one of the most secure blockchains, but I think layer-one, layer-two blockchains beyond Bitcoin, will handle the majority of transactions and activities from NFT (nonfungible tokens) to DeFi,“ Gardner said. “So I think institutions see that and insofar as they want to put capital to work in the coming months, I think that could be where they just pump the capital.”

Decentralized social media? 

The price of Decentralized Social, or DeSo, a cryptocurrency powering a blockchain that supports decentralized social media applications, surged roughly 74% to about $164 from $94, after Deso was listed at Coinbase Pro on Monday, before it fell to about $95, according to CoinGecko.

In the eyes of Nader Al-Naji, head of the DeSo foundation, decentralized social media has the potential to be “a lot bigger” than decentralized finance.

“Today there are only a few companies that control most of what we see online,” Al-Naji told Distributed Ledger in an interview. But DeSo is “creating a lot of new ways for creators to make money,” Al-Naji said.

“If you find a creator when they’re small, or an influencer, you can invest in that, and then if they become bigger and more popular, you make money and they make and they get capital early on to produce their creative work,” according to AI-Naji.

BitClout, the first application that was created by AI-Naji and his team on the DeSo blockchain, had initially drawn controversy, as some found that they had profiles on the platform without their consent, while the application’s users were buying and selling tokens representing their identities. Such tokens are called “creator coins.”

AI-Naji responded to the controversy saying that DeSo now supports more than 200 social-media applications including Bitclout. “I think that if you don’t like those features, you now have the freedom to use any app you want. Some apps don’t have that functionality at all.”

 

But Before I get to the “selling monkeys to morons” quote,

I want to talk about

THE GOOD, THE BAD, AND THE UGLY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THE GOOD

My foray into Science 2.0 and then pondering what the movement into a Science 3.0 led me to an article by Dr. Vladimir Teif, who studies gene regulation and the nucleosome, as well as creating a worldwide group of scientists who discuss matters on chromatin and gene regulation in a journal club type format.

For more information on this Fragile Nucleosome journal club see https://generegulation.org/fragile-nucleosome/.

Fragile Nucleosome is an international community of scientists interested in chromatin and gene regulation. Fragile Nucleosome is active in several spaces: one is the Discord server where several hundred scientists chat informally on scientific matters. You can join the Fragile Nucleosome Discord server. Another activity of the group is the organization of weekly virtual seminars on Zoom. Our webinars are usually conducted on Wednesdays 9am Pacific time (5pm UK, 6pm Central Europe). Most previous seminars have been recorded and can be viewed at our YouTube channel. The schedule of upcoming webinars is shown below. Our third activity is the organization of weekly journal clubs detailed at a separate page (Fragile Nucleosome Journal Club).

 

His lab site is at https://generegulation.org/ but had published a paper describing what he felt what the #science2_0 to #science3_0 transition would look like (see his blog page on this at https://generegulation.org/open-science/).

This concept of science 3.0 he had coined back in 2009.  As Dr Teif had mentioned

So essentially I first introduced this word Science 3.0 in 2009, and since then we did a lot to implement this in practice. The Twitter account @generegulation is also one of examples

 

This is curious as we still have an ill defined concept of what #science3_0 would look like but it is a good read nonetheless.

His paper,  entitled “Science 3.0: Corrections to the Science 2.0 paradigm” is on the Cornell preprint server at https://arxiv.org/abs/1301.2522 

 

Abstract

Science 3.0: Corrections to the Science 2.0 paradigm

The concept of Science 2.0 was introduced almost a decade ago to describe the new generation of online-based tools for researchers allowing easier data sharing, collaboration and publishing. Although technically sound, the concept still does not work as expected. Here we provide a systematic line of arguments to modify the concept of Science 2.0, making it more consistent with the spirit and traditions of science and Internet. Our first correction to the Science 2.0 paradigm concerns the open-access publication models charging fees to the authors. As discussed elsewhere, we show that the monopoly of such publishing models increases biases and inequalities in the representation of scientific ideas based on the author’s income. Our second correction concerns post-publication comments online, which are all essentially non-anonymous in the current Science 2.0 paradigm. We conclude that scientific post-publication discussions require special anonymization systems. We further analyze the reasons of the failure of the current post-publication peer-review models and suggest what needs to be changed in Science 3.0 to convert Internet into a large journal club. [bold face added]
In this paper it is important to note the transition of a science 1.0, which involved hard copy journal publications usually only accessible in libraries to a more digital 2.0 format where data, papers, and ideas could be easily shared among networks of scientists.
As Dr. Teif states, the term “Science 2.0” had been coined back in 2009, and several influential journals including Science, Nature and Scientific American endorsed this term and suggested scientists to move online and their discussions online.  However, even at present there are thousands on this science 2.0 platform, Dr Teif notes the number of scientists subscribed to many Science 2.0 networking groups such as on LinkedIn and ResearchGate have seemingly saturated over the years, with little new members in recent times. 
The consensus is that science 2.0 networking is:
  1. good because it multiplies the efforts of many scientists, including experts and adds to the scientific discourse unavailable on a 1.0 format
  2. that online data sharing is good because it assists in the process of discovery (can see this evident with preprint servers, bio-curated databases, Github projects)
  3. open-access publishing is beneficial because free access to professional articles and open-access will be the only publishing format in the future (although this is highly debatable as many journals are holding on to a type of “hybrid open access format” which is not truly open access
  4. only sharing of unfinished works and critiques or opinions is good because it creates visibility for scientists where they can receive credit for their expert commentary

There are a few concerns on Science 3.0 Dr. Teif articulates:

A.  Science 3.0 Still Needs Peer Review

Peer review of scientific findings will always be an imperative in the dissemination of well-done, properly controlled scientific discovery.  As Science 2.0 relies on an army of scientific volunteers, the peer review process also involves an army of scientific experts who give their time to safeguard the credibility of science, by ensuring that findings are reliable and data is presented fairly and properly.  It has been very evident, in this time of pandemic and the rapid increase of volumes of preprint server papers on Sars-COV2, that peer review is critical.  Many of these papers on such preprint servers were later either retracted or failed a stringent peer review process.

Now many journals of the 1.0 format do not generally reward their peer reviewers other than the self credit that researchers use on their curriculum vitaes.  Some journals, like the MDPI journal family, do issues peer reviewer credits which can be used to defray the high publication costs of open access (one area that many scientists lament about the open access movement; where the burden of publication cost lies on the individual researcher).

An issue which is highlighted is the potential for INFORMATION NOISE regarding the ability to self publish on Science 2.0 platforms.

 

The NEW BREED was born in 4/2012

An ongoing effort on this platform, https://pharmaceuticalintelligence.com/, is to establish a scientific methodology for curating scientific findings where one the goals is to assist to quell the information noise that can result from the massive amounts of new informatics and data occurring in the biomedical literature. 

B.  Open Access Publishing Model leads to biases and inequalities in the idea selection

The open access publishing model has been compared to the model applied by the advertising industry years ago and publishers then considered the journal articles as “advertisements”.  However NOTHING could be further from the truth.  In advertising the publishers claim the companies not the consumer pays for the ads.  However in scientific open access publishing, although the consumer (libraries) do not pay for access the burden of BOTH the cost of doing the research and publishing the findings is now put on the individual researcher.  Some of these publishing costs can be as high as $4000 USD per article, which is very high for most researchers.  However many universities try to refund the publishers if they do open access publishing so it still costs the consumer and the individual researcher, limiting the cost savings to either.  

However, this sets up a situation in which young researchers, who in general are not well funded, are struggling with the publication costs, and this sets up a bias or inequitable system which rewards the well funded older researchers and bigger academic labs.

C. Post publication comments and discussion require online hubs and anonymization systems

Many recent publications stress the importance of a post-publication review process or system yet, although many big journals like Nature and Science have their own blogs and commentary systems, these are rarely used.  In fact they show that there are just 1 comment per 100 views of a journal article on these systems.  In the traditional journals editors are the referees of comments and have the ability to censure comments or discourse.  The article laments that comments should be easy to do on journals, like how easy it is to make comments on other social sites, however scientists are not offering their comments or opinions on the matter. 

In a personal experience, 

a well written commentary goes through editors which usually reject a comment like they were rejecting an original research article.  Thus many scientists, I believe, after fashioning a well researched and referenced reply, do not get the light of day if not in the editor’s interests.  

Therefore the need for anonymity is greatly needed and the lack of this may be the hindrance why scientific discourse is so limited on these types of Science 2.0 platforms.  Platforms that have success in this arena include anonymous platforms like Wikipedia or certain closed LinkedIn professional platforms but more open platforms like Google Knowledge has been a failure.

A great example on this platform was a very spirited conversation on LinkedIn on genomics, tumor heterogeneity and personalized medicine which we curated from the LinkedIn discussion (unfortunately LinkedIn has closed many groups) seen here:

Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn

 

 

Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn

 

In this discussion, it was surprising that over a weekend so many scientists from all over the world contributed to a great discussion on the topic of tumor heterogeneity.

But many feel such discussions would be safer if they were anonymized.  However then researchers do not get any credit for their opinions or commentaries.

A Major problem is how to take the intangible and make them into tangible assets which would both promote the discourse as well as reward those who take their time to improve scientific discussion.

This is where something like NFTs or a decentralized network may become important!

See

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

 

UPDATED 5/09/2022

Below is an online @TwitterSpace Discussion we had with some young scientists who are just starting out and gave their thoughts on what SCIENCE 3.0 and the future of dissemination of science might look like, in light of this new Meta Verse.  However we have to define each of these terms in light of Science and not just the Internet as merely a decentralized marketplace for commonly held goods.

This online discussion was tweeted out and got a fair amount of impressions (60) as well as interactors (50).

 For the recording on both Twitter as well as on an audio format please see below

<blockquote class=”twitter-tweet”><p lang=”en” dir=”ltr”>Set a reminder for my upcoming Space! <a href=”https://t.co/7mOpScZfGN”>https://t.co/7mOpScZfGN</a&gt; <a href=”https://twitter.com/Pharma_BI?ref_src=twsrc%5Etfw”>@Pharma_BI</a&gt; <a href=”https://twitter.com/PSMTempleU?ref_src=twsrc%5Etfw”>@PSMTempleU</a&gt; <a href=”https://twitter.com/hashtag/science3_0?src=hash&amp;ref_src=twsrc%5Etfw”>#science3_0</a&gt; <a href=”https://twitter.com/science2_0?ref_src=twsrc%5Etfw”>@science2_0</a></p>&mdash; Stephen J Williams (@StephenJWillia2) <a href=”https://twitter.com/StephenJWillia2/status/1519776668176502792?ref_src=twsrc%5Etfw”>April 28, 2022</a></blockquote> <script async src=”https://platform.twitter.com/widgets.js&#8221; charset=”utf-8″></script>

 

 

To introduce this discussion first a few startoff material which will fram this discourse

 






The Intenet and the Web is rapidly adopting a new “Web 3.0” format, with decentralized networks, enhanced virtual experiences, and greater interconnection between people. Here we start the discussion what will the move from Science 2.0, where dissemination of scientific findings was revolutionized and piggybacking on Web 2.0 or social media, to a Science 3.0 format. And what will it involve or what paradigms will be turned upside down?

Old Science 1.0 is still the backbone of all scientific discourse, built on the massive amount of experimental and review literature. However this literature was in analog format, and we moved to a more accesible digital open access format for both publications as well as raw data. However as there was a structure for 1.0, like the Dewey decimal system and indexing, 2.0 made science more accesible and easier to search due to the newer digital formats. Yet both needed an organizing structure; for 1.0 that was the scientific method of data and literature organization with libraries as the indexers. In 2.0 this relied on an army mostly of volunteers who did not have much in the way of incentivization to co-curate and organize the findings and massive literature.

Each version of Science has their caveats: their benefits as well as deficiencies. This curation and the ongoing discussion is meant to solidy the basis for the new format, along with definitions and determination of structure.

We had high hopes for Science 2.0, in particular the smashing of data and knowledge silos. However the digital age along with 2.0 platforms seemed to excaccerbate this somehow. We still are critically short on analysis!

 

We really need people and organizations to get on top of this new Web 3.0 or metaverse so the similar issues do not get in the way: namely we need to create an organizing structure (maybe as knowledgebases), we need INCENTIVIZED co-curators, and we need ANALYSIS… lots of it!!

Are these new technologies the cure or is it just another headache?

 

There were a few overarching themes whether one was talking about AI, NLP, Virtual Reality, or other new technologies with respect to this new meta verse and a concensus of Decentralized, Incentivized, and Integrated was commonly expressed among the attendees

The Following are some slides from representative Presentations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other article of note on this topic on this Open Access Scientific Journal Include:

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model 

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

@PharmaceuticalIntelligence.com –  A Case Study on the LEADER in Curation of Scientific Findings

Real Time Coverage @BIOConvention #BIO2019: Falling in Love with Science: Championing Science for Everyone, Everywhere

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

 

Read Full Post »

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN

https://feinternational.com/blog/how-do-you-value-an-online-business/

How to Value a Website or Internet Business in 2020

 

From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.

Guide-to-Buying-an-Online-Business-vLQ

Guide-to-Buying-an-Online-Business-vHQ

We will be in touch in a few days to see if you have any questions!

Regards,


Thomas Smale
Founder

FE International, Inc.

www.feinternational.com

Follow us on FacebookLinkedIn and Twitter.

 

FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

  • Discounted Cashflow Analysis
  • Precedent Transactions
  • Earnings-Multiple
  • Traffic Valuation
  • A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:

https://feinternational.com/blog/how-do-you-value-an-online-business/

Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App

 

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS

CLAIMER:

Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 – 

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)

Example: 

Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016. 

In 2019, 

• Aviva created single handedly the FINAL version of eTOCs and 

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal. 

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume 

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented: 

• HIGH engagement, 

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content 

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

http://pharmaceuticalintelligence.com

  •  LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags

https://lnkd.in/eEw5q7N

  • BioMed e-Series: 16 Volumes in Medicine and Life Sciences

https://lnkd.in/ekWGNqA

  •  e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.

https://lnkd.in/dc2qGAK

OTHER ASSETS

  • Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
  • Asset Class V is a Gallery of ~5000 images used in the articles and books
  • Asset Class VI is the Team of Experts.
  • Asset Class VII: Royalties on BioMed e-Series

Read Full Post »

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

Curator: Aviva Lev–Ari, PhD, RN

UPDATED on 4/4/2022

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

 

UPDATED on 7/30/2021

Analysis of a corporate Stream of Innovation as reputation builder for venture valuation is presented, below

2.0 LPBI is a Very Unique Organization

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

Direct reputation, feedback reputation and signaling effects are present; and shows that better sellers are always more likely to brand stretch. The comparative statics with respect to the initial reputation level, however, are not obvious. … a higher reputation firm can earn a higher direct reputation effect premium. But a higher reputation firm also has more to lose. The trade-off between using one’s reputation and protecting it can go both ways.

Luıs M B Cabral, New York University and CEPR, 2005

Part 1:   A Digital Business Defined and the Intangible Asset of Firm’s Reputation

  1.  Claiming Distinction
  2.  Recognition Bestowed
  3.  The Technology
  4.  The Sphere of Influence
  5.  The Industrial Benefactors in Potential
  6.  The Actors at Play – Experts, Authors, Writers – Life Sciences & Medicine as it applies to HEALTH CARE
  7.  1st Level Connection on LinkedIn = +7,100 and Endorsements = +1,500
  8.  The DIGITAL REPUTATION of our Venture – Twitter for the Professional and for Institutions
  9.  Growth in Twitter Followers and in Global Reach: Who are the NEW Followers? they are OUR COMPETITION   and   other Media Establishments – that is the definition of Trend Setter, Opinion Leader and Source for Emulation
  10.  Business Aspects of the Brick & Mortar World render OBSOLETE

Part 2:   Business Perspectives on Reputation

Part 3:   Economics Perspectives on Reputation

Part 1:   A Digital Business Defined and the Intangible Asset of Firm’s Reputation

This curation attempts to teach-by-example the new reality of the Intangible Asset of Firm’s Reputation when the business is 100% in the cloud, 100% electronic in nature (paperless), the customers are the Global Universe and the organization is 100% Global and 100% virtual.

A Case in Point: Intellectual Property Production Process of Health Care Digital Content using electronic Media Channels

Optimal Testimonial of e-Product Quality and Reputation for an Open Access Online Scientific Journal pharmaceuticalintelligence.com 

 1.   Claiming Distinction

Executive Summary

WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019

2.   Recognition Bestowed 

Our Books are here

  • On 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS 

GOVERNING BOARD

ACTIVITIES

BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515

https://lnkd.in/e6WkMgF

Sixteen Volumes ARE ON AMAZON.COM, average book length – 2,400 pages

https://lnkd.in/ekWGNqA

3.   The Technology

Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences

Detailed Technology Description

LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present

4.   The Sphere of Influence 

LPBI Group’s Social Media Presence

JOURNAL Statistics on 2/24/2019

  • LPBI Platform is been used by GLOBAL Communities of Scientists for interactive dialogue of SCIENCE – Four case studies are presented in the link, below

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

Curator and Editor-in-Chief: Journal and BioMed e-Series, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

5.   The Industrial Benefactors in Potential

Opportunities Map in the Acquisition Arena

Dynamic Contents for LPBI Group’s PowerPoint Presentation

Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 

6.   The Actors at Play – Experts, Authors, Writers – Life Sciences & Medicine as it applies to HEALTH CARE

Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group

Top Authors by Number of eReaders Views

Top Articles by Number of e-Readers for All Days ending 2019-02-17

FIT Members Contribute to Opportunities Map

FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas

FIT members – Who works on WHAT?

Summer 2019 Plan – Research Associates Tasks

7.   1st Level Connection on LinkedIn = +7,100 and Endorsements = +1,500

Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN

8.   The DIGITAL REPUTATION of our Venture – Twitter for the Professional and for Institutions

Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019

LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019

Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers

REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI

9.   Growth in Twitter Followers and in Global Reach: Who are the NEW Followers: OUR COMPETITION and other Media Establishments – that is the definition of Trend Setter, Opinion Leader and Source for Emulation

@4openjournalFollows you

Follow

4open is a multi- & inter-disciplinary, online, peer-reviewed, open access journal publishing across a broad range of subjects in the STEM domain.

@roll_clausFollows you

Follow

Publishing Editor at 

@EDPSciences

@PubtextoPFollows you

Following

Pubtexto is an International online publishing organization that publishes Scientific literature through its different open access Journals.

@alexanderlabrieFollows you

Following

CEO 

@sphereinc

@BjoernBruecherFollows you

Following

THEODOR-BILLROTH-ACADEMY® 

(link: http://linkedin.com/in/bruecher)

linkedin.com/in/bruecher // 

(link: http://4open-sciences.org)

4open-sciences.org – Editor-in-Chief // Science Profile – 

(link: http://researchgate.net/profile/Bjoern)

researchgate.net/profile/Bjoern

@MPDexpertFollows you

Follow

translate research into life-changing Global manufactured Medical Products – drugs, devices, biotech, combination; anything requiring FDA approval#MedProdDev

@P_A_MORGONFollows you

Following

Life science expert & investor_travel, wine & golf amateur_Proud father of 2 girls_My Tweets are only mine 

@INmuneBioFollows you

Follow

INmune Bio, Inc. is developing therapies that harness patient’s #immunesystem to treat #cancer. Our focus is on #NKcells and #myeloid derived suppressor cells.

@sallyeavesFollows you

Following

Innovating #tech #education #business CEO CTO Advisor & Prof. #blockchain #AI 

@OxfordSBS

@Forbes

 #FinTech #speaker #SDGs #STEM #techforgood #sustainability

@sciencetracker2Follows you

You will hear more recent and cool scientific news here. Besides, some health and tech news. Follow us in

(link: http://facebook.com/sciencetracker2)

facebook.com/sciencetracker2

13.8K Following

24.6K Followers

Followed by Stanford Tweets, Biotech Week Boston, and 23 others you follow

@sgruenwaldFollows you

Following

MD, PhD, scientist, futurist, entrepreneur, managing director of 

(link: http://www.genautica.com)

genautica.com, co-founder 

(link: http://www.diagnomics.com)

diagnomics.com

(link: http://www.scoop.it/t/amazing-science)

scoop.it/t/amazing-scie…user

10.  Business Aspects of the Brick & Mortar World render OBSOLETE

Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes

Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series

2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 

Part 2: BUSINESS PERSPECTIVES on Reputation

Warren Buffett on reputation: the economic value of values, integrity and corporate culture

Warren Buffett understands that reputation and integrity have economic value. Research that shows that a good reputation is worth real money — in fact, some research indicates that a good reputation might replace a line of credit at the bank. In his book Berkshire Beyond Buffett: The Enduring Value of Values, Lawrence Cunningham argues that one of Berkshire Hathaway’s greatest assets is reputation.

https://www.finn.agency/fr/warren-buffett-reputation-berkshire-hathaway

The Value of Reputation

Thomas Pfeiffer1,2,4,*, Lily Tran5, Coco Krumme5 and David G Rand1,3,* 1 Program for Evolutionary Dynamics, FAS, 2 School of Applied Sciences and Engineering, and 3 Department of Psychology, Harvard University, Cambridge MA 02138, USA 4 New Zealand Institute for Advanced Study, Massey University, Auckland 0745, New Zealand 5 MIT Media Laboratory, Cambridge MA 02139, USA

Reputation plays a central role in human societies.

Empirical and theoretical work indicates that a good reputation is valuable in that it increases one’s expected payoff in the future. Here, we explore a game that couples a repeated Prisoner’s Dilemma (PD), in which participants can earn and can benefit from a good reputation, with a market in which reputation can be bought and sold. This game allows us to investigate how the trading of reputation affects cooperation in the PD, and how participants assess the value of having a good reputation. We find that depending on how the game is set up, trading can have a positive or a negative effect on the overall frequency of cooperation. Moreover, we show that the more valuable a good reputation is in the PD, the higher the price at which it is traded in the market. Our findings have important implications for the use of reputation systems in practice.

Keywords: evolution of cooperation; reciprocal altruism; indirect reciprocity; reputation

http://decisionlab.harvard.edu/_content/research/papers/Krumme_Pfieffer_Tran_and_Rand_Value_of_Reputation.pdf

The Impact of Reputation on Market Value by Simon Cole

One of the most familiar, but least understood, intangible assets is a firm’s reputation.

Simon Cole is the founding partner of the corporate reputation and branding consultancy Reputation Dividend (www. reputationdividend.com).

http://www.reputationdividend.com/files/4713/4822/1479/Reputation_Dividend_WEC_133_Cole.pdf

Part 3:   ECONOMICS PERSPECTIVES on Reputation

The Economics of Trust and Reputation: A Primer

Luıs M B Cabral New York University and CEPR, June 2005, lecture series at the University of Zurich

lcabral@stern.nyu.edu

https://pdfs.semanticscholar.org/24e5/2f3bd22d4bfa86902e5ae07d57039480004f.pdf

Notes on the literature

Important note: The notes in this section are essentially limited to the ideas discussed in the present version of these lectures notes. They cannot therefore be considered a survey of the literature. There are dozens of articles on the economics of reputation which I do not include here. In a future version of the text, I hope to provide a more complete set of notes on the literature. The notes below follow the order with which topics are presented.

Bootstrap models. The bootstrap mechanism for trust is based on a general result known as the folk theorem (known as such because of its uncertain origins). For a fairly general statement of the theorem (and its proof) see Fudenberg and Makin (1986). One of the main areas of application of the folk theorem has been the problem of (tacit or explicit) collusion in oligopoly. This is a typical problem of trust (or lack thereof): all firms would prefer prices to be high and output to be low; but each firm, individually, has an incentive to drop price and increase output. Friedman (1971) presents one of the earliest formal applications of the folk theorem to oligopoly collusion. He considers the case when firms set prices and history is perfectly observable. Both of the extensions presented in Section 2.2 were first developed with oligopoly collusion applications in mind. The case of trust with noisy signals (2.2.1) was first developed by Green and Porter (1984). A long series of papers have been written on this topic, including the influential work by Abreu, Pearce and Stacchetti (1990). Rotemberg and Saloner (1986) proposed a model of oligopoly collusion with fluctuating market demand. In this case, the intuition presented in Section 2.2.2 implies that firms collude on a lower price during periods of higher demand. This suggests that prices are counter-cyclical in markets where firms collude. Rotemberg and Saloner (1986) present supporting evidence from the cement industry. A number of papers have built on Rotemberg and Saloner’s analysis. Kandori (1992) shows that the i.i.d. assumption simplifies the analysis but is not crucial. Harrington (19??) considers a richer demand model and looks at how prices vary along the business cycle. The basic idea of repetition as a form of ensuring seller trustworthiness is developed in Klein and Leffler (1981). See also Telser (1980) and Shapiro (1983). When considering the problem of free entry, Klein and Leffler (1981) propose advertising as a solution, whereas Shapiro (1983) suggests low intro25 ductory prices. Section ?? is based on my own research notes. The general analysis of selfreinforcing agreements when there is an outside option of the kind considered here may be found in Ray (2002). Watson (1999, 2002) also considers models where the level of trust stars at a low level and gradually increases.

Bayesian models. The seminal contributions to the study of Bayesian models of reputation are Kreps and Wilson (1982) and Milgrom and Roberts (1982). The model in Section 3.2.1 includes elements from these papers as well as from Diamond (1989). H¨olmstrom (1982/1999) makes the point that separation leads to reduced incentives to invest in reputation. The issue of reputation with separation and changing types is treated in detail in the forthcoming book by Mailath and Samuelson (2006). In Section 3.3, I presented a series of models that deal with name as carriers of reputations. The part on changing names (Section 3.3.1) reflects elements from a variety of models, though, to the best of my knowledge, no study exists that models the process of secret, costless name changes in an infinite period adverse selection context. The study of markets for names follows the work by Tadelis (1999) and Mailath and Samuelson (2001). All of these papers are based on the Bayesian updating paradigm. Kreps (1990) presents an argument for trading reputations in a bootstrap type of model. The analysis of brand stretching (Section 3.3.3) is adapted from Cabral (2000). The paper considers a more general framework where the direct reputation, feedback reputation and signalling effects are present; and shows that better sellers are always more likely to brand stretch. The comparative statics with respect to the initial reputation level, however, are not obvious. As we saw above, a higher reputation firm can earn a higher direct reputation effect premium. But a higher reputation firm also has more to lose. The trade-off between using one’s reputation and protecting it can go both ways. For other papers on brand stretching and umbrella branding see Choi (1998), Anderson (2002).

Bibliography

Abreu, Dilip, David Pearce and Ennio Stacchetti (1990), “Toward a Theory of Discounted Repeated Games with Imperfect Monitoring,” Econometrica 58, 1041–1064. Andersson, Fredrik (2002), “Pooling reputations,” International Journal of Industrial Organization 20, 715–730. Bernhein, B. Douglas and Michael D. Whinston (1990), “Multimarket Contact and Collusive Behavior,” Rand Journal of Economics 21, 1–26. Cabral, Lu´ıs M B (2000), “Stretching Firm and Brand Reputation,” Rand Journal of Economics 31, 658-673. Choi, J.P. (1998), “Brand Extension and Informational Leverage,” Review of Economic Studies 65, 655–69. Diamond, Douglas W (1989), “Reputation Acquisition in Debt Markets,” Journal of Political Economy 97, 828–862. Ely, Jeffrey C., and Juuso Valim ¨ aki ¨ (2003), “Bad Reputation,” The Quarterly Journal of Economics 118, 785–814. Fishman, A., and R. Rob (2005), “Is Bigger Better? Customer Base Expansion through Word of Mouth Reputation,” forthcoming in Journal of Political Economy. Friedman, James (1971), “A Noncooperative Equilibrium for Supergames,” Review of Economic Studies 28, 1–12. Fudenberg, Drew and Eric Maskin (1986), “The Folk Theorem in Repeated Games with Discounting or with Imperfect Public Information,” Econometrica 54, 533–556. Green, Ed and Robert Porter (1984), “Noncooperative Collusion Under Imperfect Price Information,” Econometrica 52, 87–100. Holmstrom, Bengt ¨ (1999), “Managerial Incentive Problems: A Dynamic Perspective,” Review of Economic Studies 66, 169–182. (Originally (1982) in Essays in Honor of Professor Lars Wahlback.) Kandori, Michihiro (1992), “Repeated Games Played by Overlapping Generations of Players,” Review of Economic Studies 59, 81–92. Klein, B, and K Leffler (1981), “The Role of Market Forces in Assuring Contractual Performance,” Journal of Political Economy 89, 615–641. 27 Kreps, David (1990), “Corporate Culture and Economic Theory,” in J Alt and K Shepsle (Eds), Perspectives on Positive Political Economy, Cambridge: Cambridge University Press, 90–143. Kreps, David M., Paul Milgrom, John Roberts and Robert Wilson (1982), “Rational Cooperation in the Finitely Repeated Prisoners’ Dilemma,” Journal of Economic Theory 27, 245–252. Kreps, David M., and Robert Wilson (1982), “Reputation and Imperfect Information,” Journal of Economic Theory 27, 253–279. Mailath, George J, and Larry Samuelson (2001), “Who Wants a Good Reputation?,” Review of Economic Studies 68, 415–441. Mailath, George J, and Larry Samuelson (1998), “Your Reputation Is Who You’re Not, Not Who You’d Like To Be,” University of Pennsylvania and University of Wisconsin. Mailath, George J, and Larry Samuelson (2006), Repeated Games and Reputations: Long-Run Relationships, Oxford: Oxford University Press. Milgrom, Paul, and John Roberts (1982), “Predation, Reputation, and Entry Deterrence,” Journal of Economic Theory 27, 280–312. Phelan, Christopher (2001), “Public Trust and Government Betrayal,” forthcoming in Journal of Economic Theory. Ray, Debraj (2002), “The Time Structure of Self-Enforcing Agreements,” Econometrica 70, 547–582. Rotemberg, Julio, and Garth Saloner (1986), “A Supergame-Theoretic Model of Price Wars During Booms,” American Economic Review 76, 390–407. Shapiro, Carl (1983), “Premiums for High Quality Products as Rents to Reputation,” Quarterly Journal of Economics 98, 659–680. Tadelis, S. (1999), “What’s in a Name? Reputation as a Tradeable Asset,” American Economic Review 89, 548–563. Tadelis, Steven (2002), “The Market for Reputations as an Incentive Mechanism,” Journal of Political Economy 92, 854–882. Telser, L G (1980), “A Theory of Self-enforcing Agreements,” Journal of Business 53, 27–44. Tirole, Jean (1996), “A Theory of Collective Reputations (with applications to the persistence of corruption and to firm quality),” Review of Economic Studies 63, 1–22. 28 Watson, Joel (1999), “Starting Small and Renegotiation,” Journal of Economic Theory 85, 52–90. Watson, Joel (2002), “Starting Small and Commitment,” Games and Economic Behavior 38, 176–199. Wernerfelt, Birger (1988), “Umbrella Branding as a Signal of New Product Quality: An Example of Signalling by Posting a Bond,” Rand Journal of Economics 19, 458–466.

https://pdfs.semanticscholar.org/24e5/2f3bd22d4bfa86902e5ae07d57039480004f.pdf

Read Full Post »

Royalties in Kindle Unlimited and Kindle Owners’ Lending Library – A guide to publishing on Amazon

 

Royalties in Kindle Unlimited and Kindle Owners’ Lending Library

You’re eligible for royalty payment from Kindle Unlimited (KU, or Abonnement Kindle in France) and the Kindle Owners’ Lending Library (KOLL) for pages an individual customer reads in your book for the first time. A guide to publishing on Amazon

A customer can read your book as many times as they like, but we will only pay you for the number of pages read the first time the customer reads them. It may take months for customers to read pages in your book, but no matter how long it takes, we’ll still pay you once it happens. This is true even if your KDP Select enrollment period has expired, and you choose not to re-enroll.

Kindle Edition Normalized Page Count (KENPC v3.0)

To determine a book’s page count in a way that works across genres, devices, and display settings, we developed the Kindle Edition Normalized Page Count (KENPC). KENPC is calculated using standard formatting settings (font, line height, line spacing, etc.). We use KENPC to measure the number of pages customers read in your book, starting with the Start Reading Location (SRL) to the end of your book. Amazon typically sets SRL at chapter 1 so readers can start reading the core content of your book as soon as they open it. Non-text elements within books including images, charts and graphs will count toward a book’s KENPC.

KENPC v3.0
We released KENPC v3.0 to improve the way we measure how many pages of each book Kindle Unlimited and KOLL customers read. We’re constantly working to improve our programs and increase fairness of how we allocate the KDP Select Global Fund. These changes continue to improve the program and reward authors whose books are being borrowed and read the most by customers.

The KENPC v3.0 update applies uniformly to all KDP Select books and all versions of those books. Regardless of which version a customer may be reading, all future royalties will be paid using KENPC v3.0. If a customer previously borrowed your book and is still reading it, any new pages read will be based on KENPC v3.0.

Authors are able to earn a maximum of 3,000 Kindle Edition Normalized Pages (KENPs) read per title per customer. This means that each time your book is borrowed and read, you will receive credit for up to 3,000 pages. We believe this results in an equitable distribution of the KDP Select Global Fund.

Your book’s KENPC
You can see your book’s KENPC v3.0 listed on the “Promote and Advertise” page in your Bookshelf, and you can also see total pages read on your Sales Dashboard report. Because it’s based on default settings, KENPC v3.0 may vary from page counts listed on your Amazon detail page, which are derived from other sources.

KDP Select Global Fund
Our total payout from the KDP Select Global Fund will be unaffected by the transition to KENPC v3.0, and the amount you earn from the global fund will continue to be determined based on your share of total pages read by Kindle Unlimited (KU) and Kindle Owners’ Lending Library (KOLL) customers. The new KENPC version will be applied uniformly to all KDP Select books and used to measure all pages read.

 

Royalties

You’ll get one combined royalty payment for both KU and KOLL, paid according to the same payment schedule and payment method you selected for your other KDP sales.We review the size of the KDP Select Global Fund each month in order to make it compelling for authors to enroll their books in KDP Select. We announce the fund monthly in our community forum on kdp.amazon.com.The share of fund allocated to each country varies based on a number of factors, such as exchange rates, customer reading behavior, and local subscription pricing. Author earnings are then determined by their share of total pages read, up to a total of 3,000 pages per customer per title.

For example, here’s how we’d calculate royalty payout if $10 million in funds were available in a given month with 100 million total pages read (Note: Actual payouts vary and may be less; check your Prior Month’s Royalty Report to see your earnings):

  • Author with a 100 page bookthat was borrowed and read completely 100 times would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed and read completely 100 times would earn $2,000 ($10 million multiplied by 20,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed 100 times but only read halfway through on average would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).

We always support our authors’ efforts to promote their books, but at the same time we work to prevent any manipulation of the Kindle platform.

We do not permit authors to offer, or participate in marketing that incentivizes Kindle Unlimited or Kindle Owners’ Lending Library customers to read their books in exchange for compensation of any kind. This includes payment (whether in the form of money or gift certificates), bonus content, entry to a contest or sweepstakes, discounts on future purchases, extra product, or other gifts.

Because we’re always looking to improve our authors’ experience, we have systems in place to monitor for potential manipulation.

 

Reporting

You can see your Kindle Edition Normalized Pages (KENP) Read in your Sales Dashboard report by marketplace and title. To see historical pages read, click “Generate Report” from your Sales Dashboard and go to the Orders Report tab.

If you’re enrolled in KDP Select, you will also see the following data on your reports:

Month-To-Date Unit Sales Report: The number of pages Kindle Unlimited or KOLL customers read of your books, under the “Kindle Edition Normalized Pages (KENP) Read” column.

Prior Months’ Royalties Report: For every title, there are five possible transaction types:

  • 35%:Amount a title earned under the 35% royalty option

  • 70%:Amount a title earned under the 70% royalty option

  • KDP Select Units:Amount every KDP Select-enrolled title earned monthly through Kindle Unlimited (KU) and the Kindle Owners’ Lending Library (KOLL). If a customer reads pages in your book for the first time through KU or KOLL, you will see a separate line item indicating the accumulated number of pages read under the column “Kindle Edition Normalized Pages (KENP) Read,” and the royalty earned through KU and KOLL under the “Royalty” column.

  • Free – Promotion:Free downloads due to Free promotion campaign(s) through KDP Select.

  • Free – Price Match:Free downloads due to competitor free price match.

 

SOURCE:  https://kdp.amazon.com/en_US/help/topic/G201541130

Read Full Post »

Information Innovation and the Power of LPBI Group

Author: Rick Mandahl, MBA

LPBI Group, Business Development Team

 

“Science evolves”[1]. This simple quote from a position paper by William S. Harten[2], eminent database architect, genealogist and entrepreneur describes why he designed a new laboratory process management technology capable of adapting as processes changed. From the notion that the software system must support the science rather than the science being bound to the limitations of predefined rigid systems opened new vistas for exploration, and progress across many process intensive domains and certainly in the realm precision medicine moving into widespread clinical deployment. Science evolves.

Decades earlier Robert R. Johnson, PhD[3] leader of the GE engineering team responsible for computerizing the check processing system for the Bank of America, and in the process delivered technology that changed banking globally.  The initial exploratory endeavor began around 1950 at Stanford Research Institute [aka, SRI International, Menlo Park, CA] to address the exponential expansion of check processing bound by manual methods, thus the need to change a system that was conceived in Venice in 1431, roughly the same era as the invention of the Gutenberg Press. In Project ERMA among other things, developed the human and machine readable alphanumerics still found on every check issued in the world today. The same information could be shared by humans and machines and this realtime translation, realtime information [4] that helped manage the exponential increase in demand for financial services in the post World War Two era.

Technology supporting science, supporting commerce in our era changes centuries established methods.  Do scientific publications today advance science or simply report it? Can we do better?  How far are we beyond Gutenberg today? In 1995, Nicholas Negroponte of MIT’s Media Lab lamented that the FAX machine was barely a step beyond Gutenberg.[5] In the ensuing generation has scientific publishing advanced with the science it reports? LPBI Group thinks not.

What of new innovation in the expanding realm of life sciences? Where are the friction points that may impede progress in rapidly advancing areas of medical sciences – science whose validation rests on rigorous observation and adherence to scientific method, findings vetted by peer review and shared in scholarly journals of learned societies. Are there ways to improve, approaches to help ameliorate the current concern over “research productivity”?

Personal Reflection of an Innovation Case Study

In the early eighties upon returning from a year’s assignment in  France, I looked up a former skiing and climbing partner now Head Coach of the US Ski Team. I had heard that he was working on a new design of racing bicycle handle bars – which from afar seemed quite curious. A visit to his home near Sun Valley  resulted in an astonishing perspective. In a field where just about every innovation had been made for this simple machine, the bicycle, Boone Lennon theorized that aerodynamic improvement – the way a rider sat on the bicycle could deliver improved performance – this insight gained by observing and coaching some of the best ski racers in the world on improving their aerodynamic form in the greatest of alpine ski sports – the Downhill. Those body position principles, so important to a sport where the difference between victory or defeat is measured in hundredths of a second – those principles ought to apply to bicycle racing where on straight away courses with “two equally matched and equipped competitors, the racer with the new bars and improved aerodynamic position will win.”[6] The theory was proven when in 1989 Greg Lemond the first American to win the Tour de France used the new “aero bars” . This second of three Tour de France victories (also 1986 and 1990), was attributed by Mr. Lemond to the final time trial where he outpaced his opponent by eight seconds, the tightest margin in Tour de France history. LeMond’s superior aerodynamics brought him victory[7] – he triumphed where two comparably qualified and equipped competitors had different tools that resulted in different levels of efficiency, thus performance. 

Winning Strategy in the Information Age

In the competitive world of scientific and medical research, where can efficiencies be gained, productivity be improved?

  • Containing Information Explosion,
  • Combatting Information Obsolescence.

The game changing innovations of LPBI Group offer simple yet profound innovations to help scientists and clinicians advance at the pace they can reasonably pursue because LPBI Group’s products help keep pace with life sciences new research insights and scientific discoveries. LPBI Group  ongoing questions provide answers using curation of current scientific research results. 

  • No longer are scientific papers obsolete by the time they are published, rather
  • They are living and dynamic repositories of searchable curated knowledge to build upon, while leveraging past established benchmarks.
  • Equally qualified and equipped, what investigator, which team might advance faster?
  • Access to the best and current information would certainly be of help.
  • Access absent enormous subscription cost might help as well.
  • Accelerate information access, eliminate exorbitant access cost.

The Founders, The Finders, The Funders. 

To build a team, to create a venture, to have commercial impact, the initial founder(s) must be joined by team members who help build, refine, adapt and change as the initial concept grows to advancing stages of maturity.

The time comes when the greatest intellectual and commercial impact is likely delivered by partners whose established business channels and financial strength enable the full realization of innovation or enabling technology far beyond the operational capacities of the initial team, but exactly according their ultimate vision.

Thus, as LPBI Group grows, we seek to identify and recruit strategic partners to grow, to expand and to merge with a new structure to follow. The global community of scientists indeed all the humankind are the beneficiaries of our endeavors in knowledge creation and dissemination.


[1] UNIFlow® by UNIConnect White Paper, William S. Harten

[2] Mr. Harten in addition to being founder of UNIConnect, LC, acquired by Sunquest Information Systems is inventor of GEDCOM, the global standard for the exchange of genealogical information.

[3] Robert Royce Johnson, PhD Cal Tech, Leader of Project ERMA, VP of Engineering Emeritus- Burroughs; Professor and Chairman Emeritus Dept of Computer Science, University of Utah College of Engineering. Founder and Managing Partner n-Dimensional Visualization, LLC.

[4] Waves of Change, James L McKenney, Harvard Business School, Harvard Business Press, 1995

[5] Being Digital, Nicholas Negroponte, MIT Medial Lab, Random House 1995

[6] Personal conversations with Daniel “Boone” Lennon, Head Coach Emeritus, US Ski Team and inventor of the Aero Bar for cyclists.

[7] Simon Symthe, “How Greg LeMond’s aero bars revolutionized time trialling”, Cycling, July 9, 2015.

Read Full Post »

Scientific Articles Views: All Times 305,160 Views, Articles of >1,000 Views – Contributions of Aviva Lev-Ari, PhD, RN on Open Access Online Scientific Journal https://pharmaceuticalintelligence.com/

Reporter: Aviva Lev-Ari, PhD, RN

Top Authors for all days ending 2017-02-13 (Summarized)

 

All Time: 4/30/2012 – 2/13/2017

Author Views
2012pharmaceutical 305,160

 

Article Name VIEWS
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 9,504
Our TEAM 5,619
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 3,804
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms 3,423
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 3,328
Founder 3,097
BioMed e-Series 2,971
VISION 2,582
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community 2,551
Funding, Deals & Partnerships 2,471
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) 2,082
About 2,039
Journal PharmaceuticalIntelligence.com 2,022
Biosimilars: CMC Issues and Regulatory Requirements 1,757
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes 1,740
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB 1,539
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers 1,464
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? 1,401
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions 1,399
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® 1,382
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) 1,368
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases 1,344
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack 1,342
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease 1,257
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? 1,238
Aviva Lev-Ari, PhD, RN, Director and Founder 1,224
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 1,181
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery 1,138
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly 1,127
Treatment of Refractory Hypertension via Percutaneous Renal Denervation 1,080
Scientific and Medical Affairs Chronological CV 1,069
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin 1,063
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism 1,037
Patiromer – New drug for Hyperkalemia 1,032
Stenting for Proximal LAD Lesions 1,024

Read Full Post »

Cancer Immunotherapy Pilot Program – A Notice by the Patent and Trademark Office on 06/29/2016

ACTION

Notice.

SUMMARY

The United States Patent and Trademark Office (USPTO or Office) is implementing a pilot program to provide for earlier review of patent applications pertaining to cancer immunotherapy (“Cancer Immunotherapy Pilot Program” or “Pilot Program”) in support of the White House national $1 billion initiative to achieve ten years’ worth of cancer research in the next five years (“National Cancer Moonshot”). The USPTO will advance applications containing a claim(s) to a method of treating a cancer using immunotherapy out of turn for examination if the applicant files a grantable petition to make special under the Pilot Program. The objective of the Pilot Program is to complete the examination of the application within twelve months of special status being granted. Under the Cancer Immunotherapy Pilot Program, an application will be advanced out of turn for examination without meeting all of the current requirements of the accelerated examination program (e.g., the requirement for an examination support document) or the Prioritized Examination (Track I) program. This notice outlines the conditions, eligibility requirements, and guidelines of the Pilot Program.

TABLE OF CONTENTS

DATES:

Effective Date: June 29, 2016.

Duration: The Cancer Immunotherapy Pilot Program will run for twelve months from its effective date. Therefore, petitions to make special under the Cancer Immunotherapy Pilot Program must be filed before June 29, 2017. The USPTO may extend the Pilot Program (with or without modifications) or terminate it depending on the workload and resources needed to administer the Pilot Program, feedback from the public, and the effectiveness of the Pilot Program. If the Pilot Program is extended or terminated, the USPTO will provide notification to the public.

FOR FURTHER INFORMATION CONTACT:

Pinchus M. Laufer, Senior Legal Advisor (telephone (571) 272-7726; electronic mail at pinchus.laufer@uspto.gov) or Susy Tsang-Foster, Senior Legal Advisor (telephone (571) 272-7711; electronic mail at susy.tsang-foster@uspto.gov), of the Office of Patent Legal Administration, Office of the Deputy Commissioner for Patent Examination Policy.

For questions relating to a specific petition, please contact Gary B. Nickol, Supervisory Patent Examiner (telephone (571) 272-0835; electronic mail at gary.nickol@uspto.gov) or Brandon J. Fetterolf, Supervisory Patent Examiner (telephone (571) 272-2919; electronic mail at brandon.fetterolf@uspto.gov), of Technology Center 1600.

SUPPLEMENTARY INFORMATION:

On February 1, 2016, the White House Office of the Press Secretary announced a new, national $1 billion initiative to achieve ten years’ worth of cancer research in the next five years, with the intent to aid in the global fight against cancer. See the White House Web site at https://www.whitehouse.gov/the-press-office/2016/02/01/fact-sheet-investing-national-cancer-moonshot. To support this initiative, the USPTO is implementing the Cancer Immunotherapy Pilot Program to advance patent applications pertaining to cancer immunotherapy out of turn for examination to provide for earlier review. The objective of the Pilot Program is to complete the examination of an application containing a claim(s) to a method of treating a cancer using immunotherapy within twelve months of special status being granted. See Part XII below (Twelve-Month Goal) for more information.

New patent applications are normally taken up for examination in the order of their U.S. filing date. See section 708 of the Manual of Patent Examining Procedure (9th ed., 7th Rev., November 2015) (MPEP). The USPTO has procedures under which an application will be advanced out of turn (accorded special status) for examination if the applicant files a petition to make special under 37 CFR 1.102(c) and (d) with the appropriate showing or a request for prioritized examination under 37 CFR 1.102(e). See 37 CFR 1.102 and MPEP section 708.02. The USPTO revised its accelerated examination procedures effective August 25, 2006, requiring that all petitions to make special comply with the requirements of the revised accelerated examination (AE) program, except those based on an inventor’s health or age or the Patent Prosecution Highway (PPH) Pilot Program. See Changes to Practice for Petitions in Patent Applications To Make Special and for Accelerated Examination, 71 FR 36323 (June 26, 2006), 1308 Off. Gaz. Pat. Office 106 (July 18, 2006) (notice); see also MPEP section 708.02(a).

The USPTO is implementing the Cancer Immunotherapy Pilot Program to permit an application containing at least one claim to a method of treating a cancer using immunotherapy to be advanced out of turn (accorded special status) for examination without meeting all of the current requirements of the accelerated examination program set forth in item VIII of MPEP section 708.02(a) (e.g., examination support document) if the applicant files a grantable petition to make special under the Pilot Program. Applications that have been accorded special status based on any USPTO established procedures (such as PPH, Prioritized Examination, Accelerated Examination, Age, Health, or any other pilot program that takes up an application out of order for examination) are not eligible to be made special under the Cancer Immunotherapy Pilot Program. Applications are accorded special status under the Cancer Immunotherapy Pilot Program after grant of special status until a final disposition (defined in Part XII (Twelve-Month Goal)) is reached in the application. Under special status, an application that has not been acted on or an application with a proper RCE request will be placed on the examiner’s special new docket until a first Office action on the merits. For an application in the Pilot Program where applicant is responding to a first Office action, the application will be placed on the examiner’s regular amended docket. Under the Pilot Program, the USPTO is providing examiners with incentives to handle these applicant responses promptly.

The USPTO will accept petitions to make special under the Cancer Immunotherapy Pilot Program provided that the petitions, and applications in which they are filed, meet all of the requirements set forth in this notice. The USPTO will periodically evaluate the Pilot Program to determine whether and to what extent its coverage should be expanded. In addition, the USPTO may extend the Pilot Program (with or without modifications) or terminate it depending on the workload and resources needed to administer the Pilot Program, feedback from the public, and the effectiveness of the Pilot Program. If the Pilot Program is extended or terminated, the USPTO will provide notification to the public.

Applicants may participate in the Cancer Immunotherapy Pilot Program by filing a petition to make special under 37 CFR 1.102(d) meeting all of the requirements set forth in this notice in either a new application or in a pending application. However, continuing applications will not automatically be accorded special status based on papers filed with a petition in a parent application. Each application must, on its own, meet all requirements for special status. No fee is required. The fee for a petition to make special under 37 CFR 1.102(d) based upon the procedure specified in this notice is hereby waived.

Part I. Requirements for Petitions To Make Special Under the Cancer Immunotherapy Pilot Program: A petition to make special under the Cancer Immunotherapy Pilot Program may be granted in an application provided the eligibility requirements set forth in Part II and the following conditions are satisfied:

(1) Types of Applications. The application must be a non-reissue, non-provisional utility application filed under 35 U.S.C. 111(a), or an international application that has entered the national stage under 35 U.S.C. 371.

(2) Claim Limit and No Multiple Dependent Claims. The application must not contain more than three independent claims and more than twenty total claims. The application must not contain any multiple dependent claims. For an application that contains more than three independent claims or twenty total claims, or any multiple dependent claims, applicant must file a preliminary amendment in compliance with 37 CFR 1.121 to cancel the excess claims and/or the multiple dependent claims at the time the petition to make special is filed. The petition must include a statement that applicant agrees that the application will not have more than three independent claims, more than twenty total claims, and any multiple dependent claims while the application is in special status under the Pilot Program.

(3) The Application Must Include at Least One Method Claim of Treating a Cancer Using Immunotherapy. The application must include at least one claim to a method of treating a cancer using immunotherapy that meets the eligibility requirements in Part II of this notice. The petition must include a statement that the applicant agrees to include at least one claim to a method of treating a cancer using immunotherapy that meets the Pilot Program eligibility requirements while the application is in special status. For applications that have been previously examined, applicants will not be permitted to switch inventions in order to participate in the Pilot Program. See MPEP section 821.03.

(4) Statement Regarding Method of Treating a Cancer Using Immunotherapy. The petition to make special must state that special status under the Pilot Program is sought because the application contains a claim to a method of treating a cancer using immunotherapy that meets the eligibility requirements discussed in Part II of this notice.

(5) Statement Regarding Restriction Requirement. The petition must include a statement that, if the USPTO determines that the claims are directed to multiple inventions, applicant will agree to make an election without traverse in a telephonic interview, and elect an invention directed to a method of treating a cancer using immunotherapy that meets the eligibility requirement discussed in Part II of this notice.

(6) Statement that Special Status Was Not Previously Granted Under Any Program. The petition must state that the application has not been previously granted special status. A petition to make special under this Pilot Program may not be filed in an application in which special status was previously granted under this Pilot Program or in any other program (e.g., age, health, PPH, AE, prioritized examination).

(7) Time for Filing Petition. In general, the petition to make special under the Pilot Program must be filed (i) at least one day prior to the date that notice of a first Office action (which may be an Office action containing only a restriction requirement) appears in the Patent Application Information Retrieval (PAIR) system (applicant may check the status of an application using PAIR); or (ii) with a proper request for continued examination (RCE) that is in compliance with 37 CFR 1.114.

For patent applicants whose claimed cancer immunotherapy both (i) meets the eligibility requirements for this Pilot Program and (ii) is the subject of an active Investigational New Drug (IND) application filed by patent applicant or their agent (e.g., a licensee of the patent applicant or the patent applicant’s assignee) at the U.S. Food and Drug Administration (FDA) that has entered phase II or phase III clinical trials, the petition may be filed any time prior to an appeal or a final rejection if patent applicant certifies both (i) and (ii) in the petition. For an application that has an outstanding Office action, patent applicant must file a complete response together with the petition.

Therefore, the petition is only required to contain the above applicant certification if the patent application has received a first Office action or a request for continued examination (RCE) was not filed with the petition. By default, for applications that have been previously examined, if applicant makes the above certification in the petition, the above certification would necessarily apply to at least one of the examined claims since applicants are not permitted to switch inventions in order to participate in the Pilot Program. See MPEP section 821.03.

(8) Office Form Available for Filing Petition. Applicant should use form PTO/SB/443 for filing the petition. The form will contain a check-box for the applicant to certify that the claimed cancer immunotherapy both (i) meets the eligibility requirements for this Pilot Program and (ii) is the subject of an active IND application filed by patent applicant or their agent at the FDA that has entered phase II or phase III clinical trials. The form will be available as a Portable Document Format (PDF) fillable form in EFS-Web and on the USPTO Web site at http://www.uspto.gov/web/forms/index.html. The Office of Management and Budget (OMB) has determined that, under 5 CFR 1320.3(h), Form PTO/SB/443 does not collect “information” within the meaning of the Paperwork Reduction Act of 1995. Information regarding EFS-Web is available on the USPTO Web site at http://www.uspto.gov/learning-and-resources/support-centers/patent-electronic-business-center. Failure to use the form or its equivalent could result in the Office not recognizing the request or delays in processing the request.

(9) Electronic Filing of Petition Required. The petition to make special must be filed electronically before June 29, 2017, using the USPTO electronic filing system, EFS-Web, and selecting the document description of “Petition for Cancer Immunotherapy Pilot” on the EFS-Web screen. Any inquiries concerning electronic filing of the petition should be directed to the Electronic Business Center (EBC) at (866) 217-9197.

(10) Publication Requirement for Applications. For unpublished applications, the petition to make special must be accompanied by a request for early publication in compliance with 37 CFR 1.219. If applicant previously filed a nonpublication request in the application, applicant must file a rescission of a nonpublication request no later than the time the petition to make special is filed. Applicant may use form PTO/SB/36 to rescind the nonpublication request.

Part II. Eligibility Requirements—Applications Pertaining to Cancer Immunotherapy. To be eligible for the Cancer Immunotherapy Pilot Program, patent applications should be in the field of Oncology. The applications must contain at least one claim encompassing a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. For example, this can include the administration of cells, antibodies, proteins, or nucleic acids that invoke an active (or achieve a passive) immune response to destroy cancerous cells. The Pilot Program also will consider claims drawn to the co-administration of biological adjuvants (e.g., interleukins, cytokines, Bacillus Comette-Guerin, monophosphoryl lipid A, etc.) in combination with conventional therapies for treating cancer such as chemotherapy, radiation, or surgery. Claims to administering any vaccine that works by activating the immune system to prevent or destroy cancer cell growth are included. The Pilot Program also will consider in vivo, ex vivo, and adoptive immunotherapies, including those using autologous and/or heterologous cells or immortalized cell lines.

As in other programs, eligibility for this pilot is not restricted by (i) the nationality of the patent applicant or its agents, (ii) the location where the underlying research was undertaken or the technology was developed, or (iii) the location where the invention may be produced or manufactured.

Part III. Decision on Petition To Make Special Under the Cancer Immunotherapy Pilot Program. If applicant files a petition to make special under the Cancer Immunotherapy Pilot Program, the USPTO will decide the petition once the application has been docketed for examination. Any inquiries concerning a specific petition to make special should be directed to the appropriate Technology Center handling the petition. If the petition is granted, the application will be accorded special status under the Cancer Immunotherapy Pilot Program until a final disposition (see Part XII (Twelve-Month Goal)). Under special status, an application that has not been acted on or an application with a proper RCE request will be placed on the examiner’s special new docket until a first Office action on the merits. For an application in the Pilot Program where applicant is responding to a first Office action, the application will be placed on the examiner’s regular amended docket. Under the Pilot Program, the USPTO is providing examiners with incentives to handle these applicant responses promptly.

Applicant will be notified of the decision on the petition by the deciding official. If the application does not comply with the sequence requirements as set forth in 37 CFR 1.821 through 1.825, such that the application is not in condition for examination, or has an outstanding Office action, or if the application and/or petition does not meet all the formal requirements set forth in this notice, the USPTO will notify the applicant of the deficiency by issuing a notice. The notice will give the applicant only one opportunity to correct the deficiency. If the applicant still wishes to participate in the Cancer Immunotherapy Pilot Program, the applicant must file a proper petition and make appropriate corrections within one month or thirty days, whichever is longer. The time period for reply is not extendable under 37 CFR 1.136(a). If the applicant fails to correct the deficiency indicated in the notice within the time period set forth therein, the application will not be eligible for the Cancer Immunotherapy Pilot Program, and the application will be taken up for examination in accordance with standard examination procedures. If the application does not contain a method claim that complies with the eligibility requirements discussed in Part II of this notice, the petition will be dismissed, and the applicant will not be given an opportunity to correct the deficiency.

Part IV. Requirement for Restriction. If the claims in the application are directed to multiple inventions, the examiner may make a requirement for restriction in accordance with current restriction practice. The examiner will contact the applicant by telephone and request an oral election of a single invention for prosecution. Applicant must make an election without traverse in a telephonic interview of an invention that is to a method of treating a cancer using immunotherapy that meets the eligibility requirements for this Pilot Program. If the applicant does not respond by telephone to an examiner’s request for an election within two working days or refuses to make an election of an invention that is to a method of treating a cancer using immunotherapy, the examiner will treat the first group of claims directed to a method of treating a cancer using immunotherapy that meets the eligibility requirements of this notice as constructively elected without traverse for examination.

Part V. First Action Interview Pilot Program Not Available. Applications accepted into the Cancer Immunotherapy Pilot Program will not be eligible to participate in the First Action Interview Pilot Program. However, standard interview practice and procedures applicable to regular ex parte prosecution will still be available See MPEP section 713.02.

Part VI. Period for Reply by Applicant. The time periods set for reply in Office actions for an application granted special status under the Pilot Program will be the same as those set forth in section 710.02(b) of the MPEP. However, if an applicant files a petition for any extension of time under 37 CFR 1.136(a), the special status of the application will be terminated, and the application will be taken up for examination in accordance with standard examination procedures.

Part VII. Reply By Applicant. A reply to an Office action must be limited to responding to rejections, objections, and requirements made by the examiner. Any amendment to a non-final Office action will be treated as not fully responsive if it attempts to: (A) Add claims which would result in more than three independent claims, or more than twenty total claims, pending in the application; (B) add any multiple dependent claim; or (C) cancel all method claims to treating a cancer using immunotherapy. If a reply to a non-final Office action is not fully responsive because it does not comply with the Pilot Program claim requirements, but is a bona fide attempt to advance the application to final action, the examiner may, at his or her discretion, provide one month or thirty days, whichever is longer, for applicant to supply a fully responsive reply. Extensions of this time period under 37 CFR 1.136(a) to the notice of nonresponsive amendment will not be permitted in order for the application to remain in special status. Any further nonresponsive amendment will be treated as non-bona fide and the time period set in the prior notice will continue to run.

Part VIII. After-Final and Appeal Procedures: The mailing of a final Office action or the filing of a Notice of Appeal, whichever is earlier, is a final disposition for purposes of the twelve-month goal for the Cancer Immunotherapy Pilot Program. During the appeal process, the application will be treated in accordance with the normal appeal procedure (see MPEP Chapter 1200). Any amendment, affidavit, or other evidence after a final Office action and prior to appeal must comply with 37 CFR 1.116. The filing of an RCE is a final disposition for purposes of the twelve-month goal for the Cancer Immunotherapy Pilot Program. The application will not retain its special status after the filing of a proper RCE.

Part IX. Post-Allowance Processing. The mailing of a notice of allowance is a final disposition for the purposes of the twelve-month goal for the Pilot Program. The failure to pay the required issue fee within one (1) month of the mailing date of the Form PTOL-85 or the submission of a non-USPTO required submission under 37 CFR 1.312 will result in the allowance being processed according to the regular allowance process. A submission that includes both USPTO required changes and non-USPTO required changes under the provisions of 37 CFR 1.312 will be considered as a non-USPTO required submission for purposes of the allowance processing.

Part X. Proceedings Outside the Normal Examination Process: If an application becomes involved in proceedings outside the normal examination process (e.g., a secrecy order, national security review, interference, derivation proceeding or petitions under 37 CFR 1.181through 1.183), the USPTO will place the application in special status under the Cancer Immunology Pilot Program before and after such proceedings. During those proceedings, however, the application will not be under special status. For example, during an interference proceeding, the application will be treated in accordance with the normal interference procedures and will not be in special status under the Cancer Immunology Pilot Program. Once any one of these proceedings is completed, the application will continue in special status under the Pilot Program until it reaches a final disposition, but that may occur later than twelve months from the grant of special status under the Pilot Program.

Part XI. Withdrawal From Pilot Program. There is no provision for “withdrawal” from special status under the Pilot Program. However, filing a petition for any extension of time under 37 CFR 1.136(a) will result in the application being taken out of the Pilot Program. An applicant may abandon the application that has been granted special status under the Pilot Program in favor of a continuing application, and the continuing application will not be given special status under the Pilot Program unless the continuing application is filed with a petition to make special under the Pilot Program.

Part XII. Twelve-Month Goal. The objective of the Cancer Immunology Pilot Program is to complete the examination of an application within twelve months of special status being granted under the Pilot Program (i.e., within twelve months from the mailing date of the decision granting the petition to make special). The twelve-month goal is successfully achieved when one of the following final dispositions occurs within twelve months from the grant of special status under the Pilot Program: (1) The mailing of a notice of allowance; (2) the mailing of a final Office action; (3) the filing of an RCE; (4) the abandonment of the application; (5) or the filing of a Notice of Appeal. The final disposition of an application, however, may occur later than the twelve-month time frame in certain situations (e.g., applicant files an amendment that does not comply with the Pilot Program claim requirements or applicant petitions for extension of time under 37 CFR 1.136(a)). See Part X for more information on other events that may cause examination to extend beyond this twelve-month timeframe. In any event, however, this twelve-month time frame is simply a goal. Any failure to meet the twelve-month goal or other issues relating to this twelve-month goal are neither petitionable nor appealable matters.

Dated: June 24, 2016.

Michelle K. Lee,

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. 2016-15533 Filed 6-28-16; 8:45 am]

Read Full Post »

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

Submission for Category: Online

From: <form_engine@fs22.formsite.com> on behalf of “commawards@nas.edu” <form_engine@fs22.formsite.com>

Reply-To: <commawards@nas.edu>

Date: Wednesday, January 27, 2016 at 3:25 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: 2016 Communication Awards Nomination Form Result #9076095

The National Academies of Sciences, Engineering, and Medicine



2016 Communication Awards 
For Excellence in Reporting and Communicating

Sciences, Engineering, and Medicine

Nomination Confirmation 

Thank you for submitting a nomination for the 2016 National Academies Communication Awards.

Please select the category of your nomination: *Online
Online Entry Title: *Cancer Biology & Genomics for Disease Diagnosis, Genomics Orientations for Personalized Medicine, Metabolic Genomics and Pharmaceutics, Milestones
Online Publisher(s): *Leaders in Pharmaceutical Business Intelligence, BioMed e-Series http://pharmaceuticalintelligence.com/biomed-e-books/, Amazon.com
Online Publish Date: *2015-08-11
Online Entry Summary (Please limit to 100 words): *BioMed e-Series published in 2015 e-Books to popularize the Scientific findings of the frontier in Medicine and Life Sciences focusing on the top two Public HealthCare hazards: Cardiovascular Diseases and Cancer. The e-Series consists of medical interpretations of the most challenging causes of mortality and morbidities in Cancer Biology & Genomics for Disease Diagnosis, Genomics Orientations for Personalized Medicine, Metabolic Genomics and Pharmaceutics, the Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, the Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. Precision Medicine as in Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases.

ANNOUNCEMENT

Success – Thank You! Reference #: 9076095: The National Academies 2016 Communication Awards Nomination

I AM PROUD TO CONGRATULATE

  • Larry H Bernstein, MD, FCAP
  • Stephen J Williams, PhD
  • Tilda Barliya, PhD
  • Dror Nir, PhD

They constitute the TEAM that I nominated for 

The National Academies 2016 Communication Awards, Keck Futures Initiative – Nomination 

  • Category: Online 
  • Subject for Nomination: BioMed e-Series published in 2015 by Leaders in Pharmaceutical Business Intelligence on Amazon.com

BioMed e-Series

http://pharmaceuticalintelligence.com/biomed-e-books/

  • Cancer Biology & Genomics for Disease Diagnosis,
  • Genomics Orientations for Personalized Medicine,
  • Metabolic Genomics and Pharmaceutics,
  • Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics,
  • Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics,
  • Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases

100 words

BioMed e-Series published in 2015 e-Books to popularize the Scientific findings of the frontier in Medicine and Life Sciences focusing on the top two Public HealthCare hazards: Cardiovascular Diseases and Cancer. The e-Series consists of medical interpretations of the most challenging causes of mortality and morbidities in Cancer Biology & Genomics for Disease Diagnosis, Genomics Orientations for Personalized Medicine, Metabolic Genomics and Pharmaceutics, the Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, the Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. Precision Medicine as

https://fs22.formsite.com/res/showSuccessPage?EParam=m%2FOmK8apOTBRmouoTFrqiVATUbkBsVmGEQn3K0X14DG3VhR5CvnKsC1mzhLD6ne%2BXKN%2Fe20J%2FjE%3D

https://fs22.formsite.com/naseo-ca/2016_com_award_nom/index.html

Effective 1/27/2016

LPBI’s BioMed e-Series  was Submitted on 1/27/2016 for The National Academies of Sciences, Engineering, and Medicine



2016 Communication Awards 
For Excellence in Reporting and Communicating

Sciences, Engineering, and Medicine

The Keck Futures Initiative – a program of the National Academies of Sciences, Engineering, and Medicine, with the support of the W.M. Keck Foundation – will award four $20,000 prizes in 2016 to individuals or teams (up to four individuals associated with the creation of the work being nominated) who have developed creative, original works that address issues and advances in science, engineering and/or medicine for the general public. Nominations are accepted in four categories: Book; Film/Radio/TV; Magazine/Newspaper; and Online. The winners will be honored in the Fall 2016 and are expected to attend in person.

http://keckfutures.org/awards/nominate.html

 

Submission for Category: Magazine/Newspaper

From: <form_engine@fs22.formsite.com> on behalf of “commawards@nas.edu” <form_engine@fs22.formsite.com>

Reply-To: <commawards@nas.edu>

Date: Monday, February 1, 2016 at 11:37 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: 2016 Communication Awards Nomination Form Result #9101075

The National Academies of Sciences, Engineering, and Medicine



2016 Communication Awards 
For Excellence in Reporting and Communicating

Science, Engineering, and Medicine

Nomination Confirmation 

Thank you for submitting a nomination for the 2016 National Academies Communication Awards.

Please select the category of your nomination: *Magazine/Newspaper
Publisher(s): *Leaders in Pharmaceutical Business Intelligence – http://pharmaceuticalintelligence.com
Magazine/Newspaper Entry Summary (Please limit to 100 words): *In February 2012, a new venture was launched Doing Business As (DBA) Leaders in Pharmaceutical Business Intelligence. Founder, Pharmaceutical Business Intelligence Services is Aviva Lev-Ari, PhD, RN.

 

 

An online scientific EXCHANGE — an Open Access Online Scientific Journal for curation and reporting on frontiers in Biomedical, Genomics, Biological Sciences, Healthcare Economics, Pharmacology, Pharmaceutical & Medicine. The website, http://pharmaceuticalintelligence.com a scientific, medical and business multi expert authoring environment in LIFE SCIENCES, PHARMACEUTICAL, HEALTHCARE & MEDICINE INDUSTRIES.

 

1,879 are following our Journal, 868,702 views, 7,175 scientific comments 4,068 Scientific Articles, 472 Categories of Research, 8,267 Tags — ALL that is BioTech !!!!!!!!

  

Success – Thank You! Reference #: 9101075: Category Magazine/Newspaper -The National Academies 2016 Communication Awards Nomination

I AM HAPPY YO SHARE WITH YOU THE NOMINATION OF OUR OPEN ACCESS ONLINE SCIENTIFIC JOURNAL 

http://pharmaceuticalintelligence.com

For The National Academies 2016 Communication Awards, Keck Futures Initiative – Nomination for

Excellence in Reporting and Communicating Science, Medicine and Engineering

  • Category: Magazine/Newspaper
  • Subject for Nomination: Journal published in 2015 by Leaders in Pharmaceutical Business Intelligence 

http://pharmaceuticalintelligence.com

100 words

In February 2012, a new venture was launched Doing Business As (DBA) Leaders in Pharmaceutical Business Intelligence. Founder, Pharmaceutical Business Intelligence Services is Aviva Lev-Ari, PhD, RN.

An online scientific EXCHANGE — an Open Access Online Scientific Journal for curation and reporting on frontiers in Biomedical, Genomics, Biological Sciences, Healthcare Economics, Pharmacology, Pharmaceutical & Medicine. The website,  http://pharmaceuticalintelligence.com a scientific, medical and business multi expert authoring environment in LIFE SCIENCES, PHARMACEUTICAL, HEALTHCARE & MEDICINE INDUSTRIES.

1,879 are following our Journal, 868,702 views, 7,175 scientific comments 4,068 Scientific Articles, 472 Categories of Research, 8,267 Tags — ALL that is BioTech !!!!!!!!

https://fs22.formsite.com/res/showSuccessPage?EParam=m%2FOmK8apOTBRmouoTFrqiVATUbkBsVmGEQn3K0X14DG3VhR5CvnKsC1mzhLD6ne%2BXKN%2Fe20J%2FjE%3D

https://fs22.formsite.com/naseo-ca/2016_com_award_nom/index.html

ANNOUNCEMENT

Effective 2/1/2016

LPBI’s http://pharmaceuticalintelligence.com was Submitted on 2/1/2016 to

2016 Communication Award – Excellence in Reporting and Communicating

Science, Medicine and Engineering

The Keck Futures Initiative – a program of the National Academies of Sciences, Engineering, and Medicine, with the support of the W.M. Keck Foundation – will award four $20,000 prizes in 2016 to individuals or teams (up to four individuals associated with the creation of the work being nominated) who have developed creative, original works that address issues and advances in science, engineering and/or medicine for the general public. Nominations are accepted in four categories: Book; Film/Radio/TV; Magazine/Newspaper; and Online. The winners will be honored in the Fall 2016 and are expected to attend in person.

http://keckfutures.org/awards/nominate.html

Submission for Category: Book

Nomination of e-Book, Series A: Cardiovascular Diseases, Volume 2, Cases in Development of Scientific Curation Methodology

2016 Communication Awards Nomination Form Result #9143807

 

The National Academies of Sciences, Engineering, and Medicine

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering


Nomination Confirmation 

 

Thank you for submitting a nomination for the 2016 National Academies Communication Awards. Below please find the supporting materials necessary for your nomination category, as well as the address to which they should be sent.

Please select the category of your nomination: *

Book

Book Title: *

Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation

Publisher(s): *

Amazon Kindle Direct

Publication Date: (Please select one): *

November 2015

Book Entry Summary (Please limit to 100 words): *

The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.

Are you nominating an individual or team (up to four individuals)? *

Team

Is this a self- or third-party nomination? *

Third-Party Nomination: I am nominating someone other than myself.

First Name *

Larry H

Last Name *

Bernstein, MD, FCAP

Title *

Chief Scientific Officer

Organization *

Leaders in Pharmaceutical Business Intelligence

Street Address

54 FIRETHORN LANE

City

NORTHAMPTON

State

MA

Postal Code

01060

Country

USA

E-Mail Address *

larry.bernstein@gmail.com

Phone Number *

4137278523

URL

http://pharmaceuticalintelligence.com

First Name

AVIVA

Last Name

Lev-Ari, PhD, RN

Organization

Leaders in Pharmaceutical Business Intelligence

E-Mail Address

avivalev-ari@alum.berkeley.edu

First Name

Justin D.

Last Name

Pearlman, MD, PhD, FACC

Organization

Leaders in Pharmaceutical Business Intelligence

E-Mail Address

jdmdphd@gmail.com

First Name *

Stephen J.

Last Name *

Williams, PhD

Title *

Editor

Organization *

Leaders in Pharmaceutical Business Intelligence

Street Address

7373 Ridge Avenue

Apt/Suite/Office

116

City

Philadelphia

State

PA

Postal Code

19128

Country

USA

E-Mail Address *

sjwilliamspa@comcast.net

Phone Number *

2154870259

URL

http://pharmaceuticalintelligence.com

How did you hear about this award? (Please check all that apply): *

  • Colleague/Word of Mouth
  • Email Announcement
  • Science 2.0
  • Science Online

Read Full Post »

TSUNAMI in HealthCare under the New Name Verily.com, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

TSUNAMI in HealthCare under the New Name Verily.com

Curator: Aviva Lev-Ari, PhD, RN

 

UPDATED on 6/8/2016

The Tricorder project was announced only 3 months after Google entered the life sciences field, according to the report, and came from the same incubator which rolled out the company’s self-driving car and recently cancelled Google Glass.

Verily CEO Andrew Conrad said the scientific basis for the device was proven upon unveiling in 2014, but experts have presented conflicting views on the reality of such a device, STAT Newsreports.

“What (Verily is) really good at is physical measurements — things like temperature, pulse rate, activity level. They are not particularly good at … the chemical and the biological stuff,” Walt toldSTAT news.

Four former Verily employees said the Tricorder “has been seen internally more as a way to generate buzz than as a viable project,” according to the report.

SOURCE

http://www.massdevice.com/googles-star-trek-tricorder-bid-flops/?spMailingID=9031578&spUserID=MTI2MTQxNTczMjM5S0&spJobID=940786327&spReportId=OTQwNzg2MzI3S0

 

UPDATED on 4/16/2016

SOURCE

http://recode.net/2016/04/13/verily-alphabet-profitable/

Verily, Alphabet’s medical business, is profitable, Sergey Brin tells Googlers

20160413-verily-google-life-sciences

Verily | YouTube

SCIENCE

Publicly, Alphabet has said very little about its assortment of companies not named Google.

But internally, Alphabet is a little more forthcoming.

As we reported earlier, Nest CEO Tony Fadell appeared before Google’s all-hands meeting two weeks ago to address recent criticism of his company. During that meeting, Google co-founder and Alphabet exec Sergey Brin also defended another company under the holding conglomerate: Verily, the medical tech unit previously called Google Life Sciences.

Lumped together, Alphabet’s moonshots aren’t making money yet — but Verily is, Brin said.

Verily was the target of a scathing article — in Stat, a medical publication from the Boston Globe — scrutinizing its CEO, Andy Conrad. Several former employees told Stat that Verily suffered a talent exodus due to “derisive and impulsive” leadership by Conrad.

Here’s what Brin said in response at Google’s TGIF meeting:

I have seen a smattering of articles. And, you know, it’s actually sad to see sometimes where it appeared that … former employees or soon-to-be former employees talked to the press. But, anyhow, I can tell you what’s going on with these companies, fortunately. So in Verily’s case, despite a handful of examples, their attrition rate is below Google’s and Alphabet’s as a whole. And also, there are articles that have generally said we are blowing a lot of money and so forth. It’s true that, you know, as whole our Other Bets are not yet profitable, but some of them are, including Verily on a cash basis and increasingly so. So we’re pretty excited about these efforts.

Verily makes money through

  • partnerships with pharmaceutical companies — such as Novartis, which is licensing and planning to sell Verily’s smart contact lens — and
  • medical institutions.

It is one of three units contributing to the Other Bets total revenue ($448 million) in 2015, along with

  • Google Fiber and
  • Nest.

As we reported earlier, Nest likely brought in around $340 million of that and Fiber pulled close to $100 million, meaning that Verily’s sales were somewhere around $10 million. During the year, all the moonshot units combined reported operating losses of $3.6 billion.

Note Brin’s stipulation that Verily’s profit comes on a “cash basis.” That probably means that it’s not making profit on the normal basis, meaning when you take into account total sales minus total costs. But “cash positive” suggests they’re booking sales faster than they’re spending money, which is a positive sign. Companies normally report financials accounting for all costs. And that’s how Alphabet will next week, when it shares first-quarter results for Google and the Other Bets — although we almost certainly won’t see figures on Verily’s profitability.

We reached out to Alphabet and Verily reps for more clarity, but didn’t get any.

SOURCE

http://recode.net/2016/04/13/verily-alphabet-profitable/

 

Original Curation dated 12/14/2015

  1. Part 1: Verily in Action
  2. Part II: Innovations at a Different Scale: GDE Enterprises – A Case in Point of Healthcare in Focus – Work-in-Progress

12/31/2015 – All time

  1. Following this Journal by e-mail subscription: along with X other amazing people
  2. views
  3. comments
  4. Top Post and Pages
  5. Click Summaries
  6. Posts
  7. Categories
  8. Tags
  9. Top Authors Views

 

Part 1: Verily in Action

They write @ https://verily.com/

When Google[x] embarked on a project in 2012 to put computing inside a contact lens — an immensely challenging technical problem with an important application to health — we could not have imagined where it would lead us. As a life sciences team within Google[x], we were able to combine the best of our technology heritage with expertise from across many fields. Now, as an independent company, Verily is focused on using technology to better understand health, as well as prevent, detect, and manage disease.

Andy Conrad, Ph.D.

Chief Executive OfficerFormerly the chief scientific officer of LabCorp, Andy is a cell biologist with a doctorate from UCLA. He has always been passionate about early detection and prevention of disease: Andy co-founded the National Genetics Institute, which developed the first cost-effective test to screen for HIV in blood supply.

Brian Otis, Ph.D.

Chief Technical OfficerBrian’s team focuses on end-to-end innovation ranging from integrated circuits to biocompatible materials to sensors. He joined Google[x] as founder of the smart contact lens project and now leads our efforts across all hardware and device projects, including wearables, implanted devices, and technology like Liftware.

Jessica Mega, M.D., MPH

Chief Medical OfficerJessica leads the clinical strategy and research team at Verily. She is a board-certified cardiologist who trained and practiced at Massachusetts General Hospital and Brigham and Women’s Hospital. As a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, Jessica directed large, international trials evaluating novel cardiovascular therapies.

Linus Upson

Head of EngineeringA long-time Google software engineer, Linus has been a team lead in developing products that now help billions of people worldwide find the information they need on the Internet, including Chrome and Chrome OS. He now oversees our engineering teams.

Tom Stanis

Head of SoftwareTom spent nine years working on core Google products before joining Google[x] in 2014 to work on the Baseline Study. He now leads all our Software projects, including the development of machine learning algorithms for applications ranging from robotic-assisted surgery to diabetes management.

Vikram (Vik) Bajaj, Ph.D.

Chief Scientific OfficerVik’s broad research interests in industry and as a former academic principal investigator have included structural and systems biology, molecular imaging, nanoscience, and bioinformatics. Vik now leads the Science team in research directions related to our mission.

What are the Dimensions of the Tsumani in Healthcare?

  • prevention,
  • detection,
  • management of disease

 

Hardware

  • contact lens with an embedded glucose sensor for measuring the glucose in human tears.

Software

  • multiple sclerosis, for example, combines wearable sensors with traditional clinical tests
  • signals that could lead to new knowledge about the disease and why it progresses differently among individuals.

Clinical

  • Constituencies industry, hospitals, government, academic centers, medical societies, and patient advocacy groups
  • The Baseline Study is one of these dedicated efforts, a multi-year initiative that aims to identify the traits of a healthy human by closely observing the transition to disease.

Science

  • Understand processes that lead to conditions like cancer, heart disease, and diabetes
  • computational systems biology platforms and life sciences tools
  • bio-molecular nanotechnology for precision diagnostics and therapeutic delivery
  • advanced imaging methods for applications ranging from early diagnosis to surgical robotics.

 

FOLLOW the LEADER of Parish in the Tsunami

 

Google[x] searches for ways to boost cancer immunotherapy | Science/AAAS | News

http://news.sciencemag.org/math/2015/01/googlex-searches-ways-boost-cancer-immunotherapy

 

Google Life Sciences and American Heart Association commit $50M to study heart disease | VentureBeat

http://venturebeat.com/2015/11/08/google-life-sciences-and-american-heart-association-commit-50m-to-study-heart-disease/

 

Google Life Sciences Division Is Now Called… Verily?

http://gizmodo.com/google-life-sciences-division-is-now-called-verily-1746729894

 

WIRED: Google’s Verily Is Spinning Off ‘Verb,’ a Secretive Robot-Surgery Startup

Alphabet’s Verily, née Google Life Sciences, has announced its first spinoff, a brand new robot-assisted surgery company.

http://www.wired.com/2015/12/googles-verily-is-spinning-off-verb-a-secretive-robot-surgery-startup/

 

Google Life Sciences Rebrands as Verily under Alphabet – Fortune

Vik Bajaj, CSO

http://fortune.com/2015/12/08/google-alphabet-verily/

Verily, I Swear, Google Life Sciences debuts a New Name

By CHARLES PILLER  DECEMBER 7, 2015

http://www.statnews.com/2015/12/07/verily-google-life-sciences-name/

 

Why biomedical superstars are signing on with Google Tech firm’s ambitious goals and abundant resources attract life scientists.

Erika Check Hayden 21 October 2015

http://www.nature.com/news/why-biomedical-superstars-are-signing-on-with-google-1.18600

 

GOOGLE LIFE SCIENCES MAKES DIABETES ITS FIRST BIG TARGET

http://www.wired.com/2015/08/google-life-sciences-makes-diabetes-first-big-target/

 

GOOGLE WON THE INTERNET. NOW IT WANTS TO CURE DISEASES

http://www.wired.com/2015/08/google-won-internet-now-wants-cure-diseases/

 

Google Reveals Health-Tracking Wristband

Caroline Chen and Brian Womack

June 23, 2015 — 9:30 AM EDT

http://www.bloomberg.com/news/articles/2015-06-23/google-developing-health-tracking-wristband-for-health-research

 

Google Moves to the Operating Room in Robotics Deal With J&J

ALISTAIR BARR and JOSEPH WALKER

http://blogs.wsj.com/digits/2015/03/27/google-moves-to-the-operating-room-in-robotics-deal-with-jj/

 

Google, Biogen Seek Reasons for Advance of Multiple Sclerosis

Caroline Chen

January 27, 2015 — 9:00 AM EST

http://www.bloomberg.com/news/articles/2015-01-27/google-biogen-seek-reasons-for-advance-of-multiple-sclerosis

 

Google’s Newest Search: Cancer Cells

Google X Team Hopes to Develop Nanoparticles to Provide Early Detection of Cancer, Other Diseases

ALISTAIR BARR and RON WINSLOW

Updated Oct. 29, 2014 11:17 a.m. ET

http://www.wsj.com/articles/google-designing-nanoparticles-to-patrol-human-body-for-disease-1414515602

 

A Spoon That Shakes To Counteract Hand Tremors

Updated May 14, 201411:43 AM ET

INA JAFFE

http://www.npr.org/sections/health-shots/2014/05/13/310399325/a-spoon-that-shakes-to-counteract-hand-tremors

 

Google’s New Moonshot Project: the Human Body

Baseline Study to Try to Create Picture From the Project’s Findings

ALISTAIR BARR

Updated July 27, 2014 7:24 p.m. ET

http://www.wsj.com/articles/google-to-collect-data-to-define-healthy-human-1406246214

 

Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar

MARK SCOTT JULY 15, 2014

http://www.nytimes.com/2014/07/16/business/international/novartis-joins-with-google-to-develop-contact-lens-to-monitor-blood-sugar.html

 

Google[x] searches for ways to boost cancer immunotherapy

Jon Cohen

15 January 2015 6:25 am

http://news.sciencemag.org/math/2015/01/googlex-searches-ways-boost-cancer-immunotherapy

 

SOURCE

https://verily.com/

Part II: Innovations at a Different Scale: GDE Enterprises

A Case in Point of Healthcare in Focus –

Work-in-Progress

 

 

Read Full Post »

%d bloggers like this: